trastuzumab,pertuzumab
roche
[]
 at #asco23 presenting updated data from #phergain on ct de-escalation in her2+ ebc: phergain met its secondary endpoint with 3-years idfs 95.4% in group b and 98.8% in group b without ct 
MD, Medical Oncologist🇮🇹•Research Fellow at @JulesBordet Institute in Brussels🇧🇪 Great interest in #BreastCancer and #ImmunoOncology